Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer

被引：0
|
作者：
Raimbourg, Judith [1 ]
Cabart, Mathilde [1 ]
Joalland, Marie-Pierre [1 ]
Decaudin, Didier [2 ]
Deplater, Ludmilla [2 ]
Lanoe, Didier [1 ]
Douillard, Jean-Yves [1 ]
Bennouna, Jaafar [1 ]
Vallette, Francois [3 ]
Lalier, Lisenn [1 ]
机构：
[1] Inst Cancerol Ouest, St Herblain, France
[2] Inst Curie, Paris, France
[3] INSERM, Nantes, France
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2559
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Optimisation of EGFR TKI efficiency in the therapeutic scheme of EGFR wild-type lung cancer
    Cabart, Mathilde
    Raimbourg, Judith
    Lalier, Lisenn
    Bennouna, Jaafar
    Vallette, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Restoration of EGFR-TKI resistance by endocytosis inhibitor PAO in lung cancer with wild-type EGFR
    Kim, Boyeon
    Sung, Jae Sook
    Kim, Yeul Hong
    CANCER RESEARCH, 2016, 76
  • [3] EGFR endocytosis is a rational target in lung cancer with wild-type EGFR
    Jo, Ukhyun
    Park, Kyong Hwa
    Whang, Young M.
    Sung, Jae Sook
    Won, Nam Hee
    Park, Jong Kuk
    Kim, Yeul Hong
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
    Kim, Seo Yun
    Myung, Jae Kyung
    Kim, Hye-Ryoun
    Na, Im Il
    Koh, Jae Soo
    Baek, Hee Jong
    Kim, Cheol Hyeon
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2019, 82 (01) : 62 - 70
  • [5] EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Jo, Ukhyun
    Park, Kyong Hwa
    Whang, Young Mi
    Sung, Jae Sook
    Won, Nam Hee
    Park, Jong Kuk
    Kim, Yeul Hong
    ONCOTARGET, 2014, 5 (05) : 1265 - 1278
  • [6] EGFR endocytosis is associated with susceptibility to gefitinib in lung cancer cells with wild-type EGFR.
    Jo, Ukhyun
    Whang, Young M. I.
    Sung, Jae Sook
    Park, Kyong Hwa
    Kim, Seung Tae
    Kim, Yeul Hong
    CANCER RESEARCH, 2013, 73 (08)
  • [7] Association of systemic inflammation with survival in EGFR wild-type lung cancer
    Chen, X.
    Zhang, L.
    Liu, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer
    Kim, Boyeon
    Park, Young Soo
    Sung, Jae Sook
    Lee, Jong Won
    Lee, Saet Byeol
    Kim, Yeul Hong
    CANCER MEDICINE, 2021, 10 (01): : 372 - 385
  • [9] EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
    Chalela, Roberto
    Gonzalez-Garcia, Jose Gregorio
    Khilzi, Karys
    Curull, Victor
    Sanchez-Font, Albert
    Longaron, Raquel
    Rodrigo-Calvo, Maria Teresa
    Martin-Ontiyuelo, Clara
    Gea, Joaquim
    Bellosillo, Beatriz
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [10] To Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC with Wild-Type EGFR
    Jiang, D.
    Yu, Q.
    Zhang, X.
    Huang, F.
    Li, Y.
    Jin, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1053 - S1053
12345